BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company s Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs
News provided by
Share this article
Share this article
SUNNYVALE, Calif., May 5, 2021 /PRNewswire/ BridGene Biosciences, Inc., a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules for high value, yet traditionally undruggable targets, announced today it has raised $12 million in a Series A private financing round led by Wedo Venture Partners with additional participation by Kaitai Capital and Takeda Ventures, alongside existing investor Pangu Venture.
BridGene plans to use proceeds from the Series A financing to expand the company s proprietary covalent library to discover small-molecule ligands for a broader range of targets, advance existing oncology programs and enhance operations.